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A cohort of 65 liver transplant recipients was prospectively monitored with qualitative
polymerase chain reaction (PCR) in plasma. The ﬁrst 25 patients did not receive
prophylaxis. From a consecutive group of 40 recipients, 11 high-risk patients donor
CMV-seropositive/receptor CMV-seronegative (Dþ/R–), persistent CMV replication)
received pre-emptive oral ganciclovir (1000mg three times daily), when a marker of risk
was identiﬁed, until day 90. The overall incidence of cytomegalovirus (CMV) disease at
sixmonths was 20% (ﬁve of 25 patients) in the non-prophylaxis group and 2.5% (one of 40
patients) in the group treated with pre-emptive oral ganciclovir (relative risk, 0.11; 95%
conﬁdence interval; 0.01–0.96; P¼ 0.04). The PCR sensitivity for detecting CMV disease
was 80%, the speciﬁcity was 90%, and the positive and negative predictive values were
66% and 95%, respectively. Adverse events, graft rejection and survival were similar
between groups. We conclude that pre-emptive oral ganciclovir in high-risk patients can
reduce the risk of CMV disease.
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INTRODUCTION
Cytomegalovirus (CMV) is an important opportu-
nistic pathogen following liver transplantation
[1,2]. Active CMV replication causes various clin-
ical infectious syndromes; CMV has immunosup-
pressive properties and has been associated with
vanishing bile duct syndrome (though not in all
studies) [3]. Several prophylactic strategies have
been developed to reduce the incidence of CMV
disease. Pre-emptive therapy involves the admin-
istration of a highly effective antiviral agent to a
subgroup of patients who are at risk of disease
based on a clinical donor CMV-seropositive/
receptor CMV-seronegative (Dþ/R–) or labora-
tory risk marker. Pre-emptive therapy can be
used for patients with CMV replication on the
assumption that persistent replication is a reliable
predictor of disease [4]. CMVDNA can be detected
in the sera or plasma of liver transplant recipients
using the polymerase chain reaction (PCR) prior to
onset of symptomatic CMV infection, and could be
a potential marker for viral replication and pre-
emptive therapy [5,6].
Effective and safe oral antiviral agents need to
be developed for pre-emptive therapy to become a
promising approach. One prospective, rando-
mized, placebo-controlled study has shown uni-
versal oral ganciclovir to be effective in preventing
CMV infection and disease following liver trans-
plantation [7]. Nevertheless, its efﬁcacy in aborting
ongoing viral replication is not yet known.
This paper reports a study of the clinical value of
PCR detection of viral DNA and the efﬁcacy and




Eligible patients were over 12 years old and
were undergoing primary liver transplantation.
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Recipients of multiple organs were excluded.
The ﬁrst cohort of patients received no prophy-
laxis and they were monitored by means of CMV
DNA detection in plasma. Depending on the
results obtained from these patients, a second
cohort of patients received pre-emptive therapy
with oral ganciclovir when a marker of risk was
identiﬁed (Dþ/R– match, DNA CMV detected in
plasma in two consecutive weeks) until day 90.
Patients not treated were: those unable to take oral
medication; and those with a neutrophil count
<1000 cells/mL, platelet counts <25 000/mL, or
serum creatinine levels >300 mmol/L on entry.
The dosage of oral ganciclovir was adjusted for
impaired renal function as follows: patients
received 3000mg/day if creatinine clearance
was50mL/min, 1000mg once a day if creatinine
clearance was 25–49mL/min, 500mg once a day
if creatinine clearance was 10–24mL/min, and
500mg three times a week if creatinine clearance
was less than 10mL/min. Oral ganciclovir cap-
sules were taken 30min after a meal. Where CMV
disease was diagnosed during the study period,
the patient was routinely treated. Prophylactic
aciclovir was prohibited. Patients started selec-
tive oral decontamination when transplan-
tation was indicated, continuing until hospital
discharge. Perioperatively, patients were given
ampicillin (1 g/6 h) and ceftazidime (1 g/8h)
until 48 h after transplantation. Pneumocystis
carinii prophylaxis consisted of 500mg sulfa-
doxin/25mg pyrimethamine (Fansidar, Roche,
Switzerland) once a week, as previously described
[8].
Monitoring
Patients were routinely assessed on a daily
basis over the ﬁrst two weeks, and then weekly
until the end of the third month. Assessment
consisted of clinical examination, determination
of blood counts, creatinine, ions, liver enzymes,
and cyclosporin A/tacrolimus levels, and urine
analysis (sediment, ions and creatinine). Blood
surveillance viral cultures (shell vial) were per-
formed every two weeks for the ﬁrst month and
then at monthly intervals until the third month.
They were repeated when clinically indicated.
Detection of CMV DNA in plasma was done
at weeks 2, 3, 4, 5, 6, 7, 8, 10 and 12 after trans-
plantation. Patients were also assessed after
sixmonths.
Immunosuppressive regimen
Maintenance immunosuppression consisted of
standard triple therapy with cyclosporin or tacro-
limus, steroids and azathioprine. Rejection was
diagnosed histologically. Liver biopsy specimens
were obtained whenever hepatic dysfunction
occurred. Rejection episodes were treated with
three doses of 1 g of methylprednisolone and/or
an increase in oral prednisone that was reduced to
baseline values in ﬁve–sevendays.
Definitions
CMV infection was considered to exist when the
virus was isolated either in blood or in a biopsy.
CMV disease was considered to exist when the
culture or histologic evidence of CMV infection
was accompanied by consistent symptoms. Viral
syndrome was deﬁned as persistent fever and
leukopenia, with or without anemia and thrombo-
penia,which could not be attributed to other causes
in a patient with evidence of infection according to
culture. Organ diseasewas deﬁned as symptomatic
dysfunction with histologic evidence of infection
(deﬁnitive diagnosis) or viral isolation in a biopsy
culturewithout histologic evidence (probable diag-
nosis). CMV replicationwas considered ‘persistent’
when CMVDNAwas detected in plasma over two
consecutive weeks.
Plasmatic PCR procedure (nested PCR)
Plasma samples were maintained at 20 8C until
processing for a period ranging from one to ﬁve -
days. EDTAwas used in plasma collection. Nucleic
acids were extracted from plasma with 0.1M
NaOH (v/v) for 1 h at 37 8C and neutralized with
0.1M HCl. The solution was treated with phenol–
chloroform and chloroform–isoamyl alcohol. The
primers used in the nested PCR assay were taken
from the fourth exon of the CMV IEA1 gene
(Towne strain). The outer primer pair was 50-
CAAGCGGCCTCTGATAACCAAGC-30 comple-
mentary to the coding DNA strand nucleotides
731–753, and 50-CTCTTCCTCTGGGGCAACTTC-
CTC-30 complementary to the non-coding DNA
nucleotides 1167–1144. These primers ampliﬁed
a 438-bp fragment of DNA. The inner pairs of
primers were 50-GCCGATCCTCTGAGAGTCTG-
CTCTC-30 complementary to coding strand
nucleotides 829–851, and 50-CAGCCACAATTA-
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CTGAGGACAGAGG-30 complementary to non-
coding DNA nucleotides 1019–994. These primers
ampliﬁed a 190-bp fragment of DNA. Reaction
mixtures consisted of 5 mL of plasma, 20 pmol
(0.4 mM) of each oligonucleotide primer, 1.25U
of the enzyme Taq polymerase (Perkin Elmer
Cetus, Norwalk, CT, USA), 200 mM (each) of dox-
ynucleotide triphosphates (dATP, dCTP, dGPT
and dTTP), 50mM KCl, 10mM Tris-HCl
(pH 9.0), 2.5mM MgCl2, and 1% Triton X-100, to
a total volume of 50 mL in a microcentrifuge tube.
In the ﬁrst ampliﬁcation, tubes were subjected to
30 cycles (94 8C for 1min, 65 8C for 1min, 72 8C for
1minþ 10 s) in a DNA thermocycler (Perkin Elmer
Cetus). In the second ampliﬁcation, 5 mL of ampli-
ﬁed solution was used, employing the same reac-
tion mixture. In this case, samples were subjected
to 40 cycles (94 8C for 1min, 65 8C for 1min, 72 8C
for 1minþ 10 s). Ampliﬁed PCR products were
electrophoresed on an agarose gel and visualized
with ethidium bromide under ultraviolet light. For
each PCR batch, three tubes containing the reac-
tion mixture but no target DNA were run. All
tubes containing the reaction mixture but no target
DNA yielded negative results.
Statistical analysis
The Student t-test was used for quantitative data
and the chi-square test for qualitative data. The
primary endpoint in this study was time to devel-
opment of CMV disease during the six-month
study period. Secondary endpoints were patient
survival, acute graft rejection, and graft loss.
Kaplan–Meier product limit estimates of event
rates were calculated at sixmonths. The Cox pro-
portional hazards model was used to estimate
relative risk for the treatment effect. Logistical
regression was used to analyze intergroup differ-
ences in graft rejection and graft loss.
RESULTS
Demographics
Between November 1995 and December 1997, 80
patients received a liver transplant at this center.
Fifteen patients were excluded from the study: ten
patients had exclusion criteria (unable to take oral
medication, three patients; neutrophil count
<1000 cells/mL, two patients; platelets counts
<25 000/mmol, two patients; serum creatinine
>300 mmol/L, three patients), four patients were
not able to comply with the study protocol, and
one patient was unlikely to survive for more than
24 h. Complete six-month data were thus available
for 65 patients (Figure 1). A ﬁrst cohort of 25
patients not receiving viral prophylaxis was
assessedwith qualitative PCR in plasma. A second
consecutive cohort of 40 patients was treated with
pre-emptive oral ganciclovir in Dþ/R– patients
and in patients with positive PCR in plasma in two
consecutive weeks. The two cohorts were well
matched for sex, age, primary liver disease and
immunosuppression (Table 1). In the ﬁrst cohort of
25 patients, 23 recipients were CMV seropositive
(Rþ) but received CMV-seropositive or -seronega-
tive donor organs; two recipients were CMV ser-
onegative but received CMV-seropositive donor
organs (Dþ/R–). In the second cohort of 40
patients, 38 recipients were Rþ, one patient was
Dþ/R–, and one patient was CMV seronegative,
but the donor’s CMV serology was unknown.
Ability of persistent replication assessed by
qualitative PCR to predict CMV disease
The value of persistent CMV replication as a
predictor of CMV disease was assessed by 2 2
table analysis (Table 2). Of the ﬁve patients with
CMV disease, four (80%) also displayed persistent
replication. One patient with CMV hepatitis had
never presented CMV replication in plasma. This
Figure 1 Trial profile.
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analysis revealed a sensitivity of 80%, a speciﬁcity
of 90%, and positive and negative predictive
values of 66% and 95%, respectively. One Dþ/
R– patient presented a second positive PCR at the
same time as CMV hepatitis. Four Rþ patients
displayed persistent second positive PCRs for a
minimum of sevendays (mean, 21; median, 14)
prior to the onset of CMV disease. The other Dþ/
R– patient died on day 34, preventing adequate
follow-up. Excluding the two Dþ/R– patients,
analysis revealed a sensitivity of 75%, a speciﬁcity
of 89%, and positive and negative predictive
values of 60% and 94%, respectively.
Clinical outcome of prophylaxis with oral
ganciclovir
We ﬁrst analyzed the risk of CMV disease asso-
ciated with both policies; ‘wait and treat’ com-
pared with pre-emptive oral ganciclovir (Table 3).
The incidence of CMV disease at sixmonths was
20% (5/25 patients) in the group without prophy-
laxis (‘wait and treat’ policy) and 2.5% (1/40
patients) in the group treated with pre-emptive







Mean age (years) 48 12 48 13 NS
Sex male 17 (68%) 27 (67%) NS
Primary liver disease
Alcohol 8 (32%) 5 (12.5%) NS
Hepatitis C virus 8 (32%) 20 (50%)
Primary biliary cirrhosis 1 (4%) 2 (5%)
Fulminant hepatic failure 2 (8%) 1 (2.5%)
Hepatitis B virus 2 (8%) 6 (15%)
Other 4 (16%) 6 (15%)
Pretransplant CMV serology
Receptor positive 23 (92%) 38 (95%) NS
Donor positive/receptor negative 2 (6%) 1 (2.5%)
Donor unknown/receptor negative 0 1 (2.5%)
NS, not significant; Student t-test and chi-square test.
Table 1 Patient demographics, pri-
mary liver disease and CMV sero-
status
Table 2 Number of liver transplant recipients from the
first cohort (‘wait and treat’ policy) with CMV disease as a




Present 4 2 6
Absent 1 18 19
Total 5 20 25
Sensitivity¼ 4/5¼ 80%; specificity¼ 18/20¼ 90%; positive
predictive value¼ 4/6¼ 66%; negative predictive value¼
18/19¼ 95%.







‘Wait and treat’ (n¼ 25) 5 (20%) Reference –
Pre-emptive oral GCV (n¼ 40) 1 (2.5%) 0.11 (0.01–0.96) 0.04
CMV replication
Replication without oral GCV (n¼ 6) 4 (66.6%) Reference
Replication with oral GCV (n¼ 11) 0 (0%) 0.05 (0.01–0.25) < 0.01
CMV, cytomegalovirus; GCV, ganciclovir; NS, not significant.
Kaplan-Meier estimates and Cox proportional hazards regression.
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P¼ 0.04). Eleven patients received oral ganciclovir
in the pre-emptive group during a median of
50 days (range, 37–65). Oral ganciclovir was admi-
nistered with a median delay of three days (range,
one–ﬁve days) after the second positive PCR was
observed. All patients were PCR negative after
threeweeks of treatment.
In the ‘wait and treat’ cohort, ﬁve patients
developed CMV disease; viral syndrome, two
patients, enteritis, one patient, and hepatitis, two
patients. Before transplantation, four patients were
Dþ/Rþ and one patient was Dþ/R– (hepatitis).
All ﬁve patients but one had persistent CMV
replication (two consecutive positive PCRs). One
Dþ/R– patient presented a second positive PCR
at the same time as CMV hepatitis. The patient
displaying CMV disease from the pre-emptive
therapy groupwas CMV seropositive before trans-
plantation and he never received oral ganciclovir,
since plasma PCR was always negative. The
patient presented local reactivation of CMV in
the allograft (hepatitis). Two of the 48 patients
(4.2%) with negative PCR CMV in all measure-
ments developed CMV disease.
All patients with CMV disease responded to a
single course of intravenous ganciclovir. None of
these patients developed recurrent CMV disease.
Between the three-month and the six-month fol-
low-up visits, no patients from either group devel-
oped CMV disease.
The efﬁcacy of oral ganciclovir in preventing
CMV disease was also analyzed as a function of
persistent CMV replication. Oral ganciclovir was
associated with a signiﬁcant reduction in rate of
CMV disease in PCR-positive patients receiving
oral ganciclovir (11 patients) as compared with
non-treated PCR-positive patients (six patients).
The incidence of CMV disease at 6months was
66.6% (4/6 patients) in PCR-positive patients not
receiving oral ganciclovir, compared with 0% (0/
11 patients) in PCR-positive patients treated with
oral ganciclovir. Ganciclovir prophylaxis pro-
duced an overall reduction of CMV disease in
patients with persistent replication (relative risk
(95% CI), 0.05 (0.01–0.25), P< 0.01).
During the six-month study period, one patient
(9%) developed symptomatic herpes simplex virus
infection in the group of patients with positive
PCR treated with oral ganciclovir; this occurred
twoweeks before oral ganciclovir was indicated.
One patient (16.6%) in the group of positive PCR
without prophylaxis and six patients (12.5%) in the
group of negative PCR had herpes simplex virus
disease.
Nointergroupdifferenceswererecordedinterms
ofeither the incidenceofacutegraft rejectionorgraft
loss during the six-month follow-up period.
Adverse events during oral ganciclovir
treatment
The most common adverse events during the six-
month study period were diarrhea, anemia and
elevated serum creatinine. These occurred with
similar frequency in the ‘wait and treat’ group
and in the pre-emptive ganciclovir group: diar-
rhea, 28% (7/25 patients) versus 30% (12/40
patients); anemia, 60% (15/25 patients) versus
62.5% (25/40 patients); elevated serum creatinine
( 2), 16% (4/25 patients) versus 17.5% (7/40
patients).
Survival
Mortality rates at the end of the sixth month were
16% (four of 25 patients) in the non-prophylaxis
cohort and 10% (four of 40 patients) in the cohort
treated with pre-emptive oral ganciclovir, but dif-
ferences were not signiﬁcant. One of the six
patients (16.6%) developing positive plasma
PCR and not treated with oral ganciclovir died,
but death was not directly attributable to CMV
disease.
DISCUSSION
The ﬁrst part of this study was designed to deter-
mine whether persistent CMV replication, deﬁned
as positive plasmatic PCR in two consecutive
weeks, could be used as a marker for pre-emptive
therapy. Our results suggest that persistent repli-
cation is a marker of the risk of CMV disease and
that plasmatic PCR provides a high degree of
sensitivity and speciﬁcity for predicting the onset
of CMV disease. It may be a useful laboratory
marker for pre-emptive therapy.
Some authors have detected CMV DNA in
plasma even when cell-free virus cannot be
detected in plasma by standard culture techni-
ques, reﬂecting the extremely high sensitivity of
PCR for the detection of small amounts of extra-
cellular free virus or viral fragments [5,9,10]. It
gives rise to false positives and low speciﬁcity
when only one sample is taken into account. Other
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authors have reported a high positive predictive
value of one positive PCR for predicting CMV
disease in transplant patients using the Cobas
Amplicor CMV Monitor PCR test [5]. Neverthe-
less, we have observed that intermittent DNAemia
in asymptomatic patients accounted for false posi-
tives [10]. This could reﬂect a higher sensitivity of
our PCR test, which could detect replication in
clinically insigniﬁcant sites, such as the genitour-
inary tract; in most cases, positive results are
followed in later weeks by negative results. The
data obtained here suggest that speciﬁcity for
predicting CMV disease is high, if we consider
only those patients with positive results in two
consecutive weeks as being at risk. Although viral
load quantiﬁcation has been proposed as an alter-
native to increased speciﬁcity, a study has shown
that quantitative PCR from peripheral blood pro-
vided no additional advantage to qualitative PCR
for predicting CMV disease [9]. Although the
detection of persistent CMV replication using
PCR in plasma was not followed by disease in
one of every three patients (positive predictive
value of 66%), the relative risk of CMV disease
related to non-treated persistent replication was
extremely high. Furthermore, with a negative pre-
dictive value of 95%, the chance of a patient having
CMV disease without CMV persistent replication
was extremely low. Therefore, detection of persis-
tent DNAemia in plasma is a good marker for
guiding pre-emptive therapy.
CMV-naive patients (Dþ/R–) may represent an
exception for early identiﬁcation of patients who
will later develop CMV disease. A CMV-naive
patient in the ‘wait and treat’ group simulta-
neously developed CMV disease and the second
positive PCR. It has recently been shown that in
Dþ/R– liver transplant patients not receiving anti-
viral prophylaxis, all viral load levels are sufﬁcient
for identifying patients developing the disease
[11], raising the question of whether surveillance
of CMV replication is indicated in CMV-naive
patients. Thus, Dþ/R– serostatus provides prog-
nostic information because it identiﬁes a subgroup
of patients whowill develop high CMV loads post-
transplant [4].
For a prophylactic regimen to be widely applic-
able, it must be effective, practical, safe and inex-
pensive. A recent study has shown that oral
ganciclovir at a dosage of 3 g/day until day 98
post-transplant is a safe and effective method for
preventing CMV disease after liver transplanta-
tion [7]. Oral ganciclovir was effective and safe in
all the subgroups analyzed. This was the ﬁrst
study to demonstrate a signiﬁcant beneﬁt for anti-
viral prophylaxis in the Dþ/R– subgroup or in
liver transplant recipients, who are at the greatest
risk from CMV disease. Two potential concerns
regarding universal prophylaxis with oral ganci-
clovir are the possible emergence of drug-resistant
viral strains and its economic cost. Optimization of
pre-emptive therapy requires further develop-
ment of effective oral drugs that may be used in
asymptomatic outpatients when the laboratory
marker is positive.
The second part of our study was designed to
determine whether pre-emptive oral ganciclovir
was effective and safe for preventing CMV dis-
ease. Oral ganciclovir may reduce the incidence of
symptomatic CMV infection without severe side
effects, avoiding the cost and risk of universal
prophylaxis. These results suggest that viral repli-
cation may be aborted in seropositive receptors
before CMV disease is achieved, by using oral
ganciclovir. Recommended target serum concen-
trations of ganciclovir obtained with the oral for-
mulation are 0.5–1.0 mg/mL, which is within the
IC50 range of most CMV isolates [12], and which
would effectively abort the disease process when a
risk patient is identiﬁed rapidly. Nevertheless,
ganciclovir levels were not determined in this
study. Since Dþ/R– serostatus is a known risk
factor of CMV disease, we decided to initiate oral
ganciclovir immediately after transplantation in
this patient subgroup. The only Dþ/R– patient
included in this second cohort never developed
viral replication or CMV disease during the fol-
low-up period.
The primary toxicity of ganciclovir is myelotoxi-
city [13,14]. Whenever oral ganciclovir was indi-
cated, it was not associated with severe
myelotoxicity. The drug was well tolerated with-
out signiﬁcant side effects.
Based on the results obtained here, we believe
that the protocol used offers several advantages
over universal prophylaxis with oral ganciclovir. It
signiﬁcantly reduced the use of the drug, since
Dþ/R– accounted for few patients, and CMV-
positive receptors with persistent replication
corresponded to only one of every three or four
patients. The emergence of resistance is always a
cause for concern [15,16], particularly in light of
a recent article showing that application of the
pre-emptive therapy strategy in Dþ/R– patients
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notably increases the risk of generating ganciclo-
vir-resistant CMV [17]. The reduction in medica-
tion costs will probably be cancelled out by an
increase in viral surveillance costs.
Similar results have been observed in another
study, in which pre-emptive oral ganciclovir was
guided by antigenemia [18]. An interesting differ-
ence between the two studies is that, whereas in
the present study oral ganciclovir (1000mg three
times daily) was administered until week 12, the
other study used a loading dose (2000mg three
times daily) for twoweeks, followed by a standard
dosage (1000mg three times daily) for fourweeks.
Since all of our patients were PCR negative after
threeweeks of treatment, we suggest that the load-
ing dose can be avoided.
This study has clear limitations. First, the sam-
ple size was small and the follow-up was short.
Second, this was not a randomized study. For
these reasons, it can only be considered as a pro-
spective pilot study. A prospective, randomized
and controlled trial comparing universal oral gan-
ciclovir with the approach adopted here is
required in order to establish its value. Future
studies should also address the potential value
of pre-emptive therapy using other available
anti-CMV oral drugs (valganciclovir, 1263W94,
etc.) and the risk of generating ganciclovir-resis-
tant CMV strains.
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